Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Novel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase Complementation Assay.

Holzer M, Schade N, Opitz A, Hilbrich I, Stieler J, Vogel T, Neukel V, Oberstadt M, Totzke F, Schächtele C, Sippl W, Hilgeroth A.

Molecules. 2018 Sep 12;23(9). pii: E2335. doi: 10.3390/molecules23092335.

2.

TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole.

Oberstadt M, Stieler J, Simpong DL, Römuß U, Urban N, Schaefer M, Arendt T, Holzer M.

Sci Rep. 2018 Feb 2;8(1):2248. doi: 10.1038/s41598-018-20565-0.

3.

CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.

Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W, Waldschmidt D, Jacobasch L, Wilhelm M, Rau BM, Grützmann R, Weinmann A, Maschmeyer G, Pelzer U, Stieler JM, Striefler JK, Ghadimi M, Bischoff S, Dörken B, Oettle H, Riess H.

J Clin Oncol. 2017 Oct 10;35(29):3330-3337. doi: 10.1200/JCO.2017.72.6463. Epub 2017 Aug 17.

PMID:
28817370
4.

Is sporadic Alzheimer's disease a developmental disorder?

Arendt T, Stieler J, Ueberham U.

J Neurochem. 2017 Nov;143(4):396-408. doi: 10.1111/jnc.14036. Epub 2017 May 28. Review.

PMID:
28397252
5.

Tau and tauopathies.

Arendt T, Stieler JT, Holzer M.

Brain Res Bull. 2016 Sep;126(Pt 3):238-292. doi: 10.1016/j.brainresbull.2016.08.018. Epub 2016 Sep 9. Review.

PMID:
27615390
6.

Second-Line Treatment in Pancreatic Cancer Patients: Who Profits?--Results From the CONKO Study Group.

Sinn M, Dälken L, Striefler JK, Bischoff S, Schweitzer N, Pelzer U, Dörken B, Riess H, Stieler JM.

Pancreas. 2016 Apr;45(4):601-5. doi: 10.1097/MPA.0000000000000533.

PMID:
26646276
7.

Tau phosphorylation-associated spine regression does not impair hippocampal-dependent memory in hibernating golden hamsters.

Bullmann T, Seeger G, Stieler J, Hanics J, Reimann K, Kretzschmann TP, Hilbrich I, Holzer M, Alpár A, Arendt T.

Hippocampus. 2016 Mar;26(3):301-18. doi: 10.1002/hipo.22522. Epub 2015 Oct 13.

PMID:
26332578
8.

Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial.

Pelzer U, Opitz B, Deutschinoff G, Stauch M, Reitzig PC, Hahnfeld S, Müller L, Grunewald M, Stieler JM, Sinn M, Denecke T, Bischoff S, Oettle H, Dörken B, Riess H.

J Clin Oncol. 2015 Jun 20;33(18):2028-34. doi: 10.1200/JCO.2014.55.1481. Epub 2015 May 18.

PMID:
25987694
9.

Brain hypometabolism triggers PHF-like phosphorylation of tau, a major hallmark of Alzheimer's disease pathology.

Arendt T, Stieler J, Holzer M.

J Neural Transm (Vienna). 2015 Apr;122(4):531-9. doi: 10.1007/s00702-014-1342-8. Epub 2014 Dec 6. Review.

PMID:
25480630
10.

Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.

Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, Görner M, Mölle M, Greten TF, Lakner V, Bischoff S, Sinn M, Dörken B, Pelzer U.

J Clin Oncol. 2014 Aug 10;32(23):2423-9. doi: 10.1200/JCO.2013.53.6995. Epub 2014 Jun 30.

PMID:
24982456
11.

KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.

Sinn BV, Striefler JK, Rudl MA, Lehmann A, Bahra M, Denkert C, Sinn M, Stieler J, Klauschen F, Budczies J, Weichert W, Stenzinger A, Kamphues C, Dietel M, Riess H.

Pancreas. 2014 May;43(4):578-83. doi: 10.1097/MPA.0000000000000077.

PMID:
24681874
12.

Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial.

Pelzer U, Hilbig A, Stieler JM, Bahra M, Sinn M, Gebauer B, Dörken B, Riess H.

BMC Cancer. 2014 Mar 19;14:204. doi: 10.1186/1471-2407-14-204.

13.

Involvement of ESCRT-II in hepatitis B virus morphogenesis.

Stieler JT, Prange R.

PLoS One. 2014 Mar 10;9(3):e91279. doi: 10.1371/journal.pone.0091279. eCollection 2014.

14.

Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study.

Sinn M, Striefler JK, Sinn BV, Sallmon D, Bischoff S, Stieler JM, Pelzer U, Bahra M, Neuhaus P, Dörken B, Denkert C, Riess H, Oettle H.

J Surg Oncol. 2013 Nov;108(6):398-402. doi: 10.1002/jso.23409. Epub 2013 Aug 23.

PMID:
24038103
15.

Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first-line therapy.

Pelzer U, Hilbig A, Sinn M, Stieler J, Bahra M, Dörken B, Riess H.

Front Oncol. 2013 Jun 14;3:155. doi: 10.3389/fonc.2013.00155. eCollection 2013.

16.

Biliary tract cancer: a survey regarding the current oncological daily care practice in Germany.

Sinn M, Bischoff S, Nehls O, Pelzer U, von Weizsäcker F, Kubicka S, Stieler JM, Caca K, Riess H.

Onkologie. 2012;35(12):755-60. doi: 10.1159/000345115. Epub 2012 Nov 20.

17.

Role of human sec63 in modulating the steady-state levels of multi-spanning membrane proteins.

Mades A, Gotthardt K, Awe K, Stieler J, Döring T, Füser S, Prange R.

PLoS One. 2012;7(11):e49243. doi: 10.1371/journal.pone.0049243. Epub 2012 Nov 15.

18.

L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial.

Kraft M, Kraft K, Gärtner S, Mayerle J, Simon P, Weber E, Schütte K, Stieler J, Koula-Jenik H, Holzhauer P, Gröber U, Engel G, Müller C, Feng YS, Aghdassi A, Nitsche C, Malfertheiner P, Patrzyk M, Kohlmann T, Lerch MM.

Nutr J. 2012 Jul 23;11:52. doi: 10.1186/1475-2891-11-52.

19.

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.

Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, Riess H, Oettle H.

Eur J Cancer. 2011 Jul;47(11):1676-81. doi: 10.1016/j.ejca.2011.04.011. Epub 2011 May 10.

PMID:
21565490
20.

First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group.

Pelzer U, Arnold D, Reitzig P, Herrenberger J, Korsten FW, Kindler M, Stieler J, Dörken B, Riess H, Oettle H.

Cancer Chemother Pharmacol. 2011 Nov;68(5):1173-8. doi: 10.1007/s00280-011-1602-3. Epub 2011 Mar 15.

PMID:
21400239

Supplemental Content

Loading ...
Support Center